Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 43 entries
Sorted by: Best Match Show Resources per page
CORRIGENDUM: Commentary on Pharmacometrics for Immunotherapy.

CPT: pharmacometrics & systems pharmacology

Garrido MJ, Berraondo P, Trocóniz IF.
PMID: 28425210
CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):277. doi: 10.1002/psp4.12186. Epub 2017 Apr 06.

No abstract available.

Cite
Garrido MJ, Berraondo P, Trocóniz IF. CORRIGENDUM: Commentary on Pharmacometrics for Immunotherapy. CPT Pharmacometrics Syst Pharmacol. 2017;6(4):277doi: 10.1002/psp4.12186.
Garrido, M. J., Berraondo, P., & Trocóniz, I. F. (2017). CORRIGENDUM: Commentary on Pharmacometrics for Immunotherapy. CPT: pharmacometrics & systems pharmacology, 6(4), 277. https://doi.org/10.1002/psp4.12186
Garrido, M J, et al. "CORRIGENDUM: Commentary on Pharmacometrics for Immunotherapy." CPT: pharmacometrics & systems pharmacology vol. 6,4 (2017): 277. doi: https://doi.org/10.1002/psp4.12186
Garrido MJ, Berraondo P, Trocóniz IF. CORRIGENDUM: Commentary on Pharmacometrics for Immunotherapy. CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):277. doi: 10.1002/psp4.12186. Epub 2017 Apr 06. PMID: 28425210; PMCID: PMC5397560.
Copy Download .nbib Format: NLM
Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy.

Journal for immunotherapy of cancer

Alvarez M, Molina C, De Andrea CE, Fernandez-Sendin M, Villalba M, Gonzalez-Gomariz J, Ochoa MC, Teijeira A, Glez-Vaz J, Aranda F, Sanmamed MF, Rodriguez-Ruiz ME, Fan X, Shen WH, Berraondo P, Quintero M, Melero I.
PMID: 34824158
J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-002953.

BACKGROUND: BO-112 is a nanoplexed form of polyinosinic:polycytidylic acid that acting on toll-like receptor 3 (TLR3), melanoma differentiation-associated protein 5 (MDA5) and protein kinase RNA-activated (PKR) elicits rejection of directly injected transplanted tumors, but has only modest efficacy against...

Cite
Alvarez M, Molina C, De Andrea CE, et al. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. J Immunother Cancer. 2021;9(11)doi: 10.1136/jitc-2021-002953.
Alvarez, M., Molina, C., De Andrea, C. E., Fernandez-Sendin, M., Villalba, M., Gonzalez-Gomariz, J., Ochoa, M. C., Teijeira, A., Glez-Vaz, J., Aranda, F., Sanmamed, M. F., Rodriguez-Ruiz, M. E., Fan, X., Shen, W. H., Berraondo, P., Quintero, M., & Melero, I. (2021). Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. Journal for immunotherapy of cancer, 9(11), . https://doi.org/10.1136/jitc-2021-002953
Alvarez, Maite, et al. "Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy." Journal for immunotherapy of cancer vol. 9,11 (2021). doi: https://doi.org/10.1136/jitc-2021-002953
Alvarez M, Molina C, De Andrea CE, Fernandez-Sendin M, Villalba M, Gonzalez-Gomariz J, Ochoa MC, Teijeira A, Glez-Vaz J, Aranda F, Sanmamed MF, Rodriguez-Ruiz ME, Fan X, Shen WH, Berraondo P, Quintero M, Melero I. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-002953. PMID: 34824158; PMCID: PMC8627419.
Copy Download .nbib Format: NLM
Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors.

Journal for immunotherapy of cancer

Tenesaca S, Vasquez M, Alvarez M, Otano I, Fernandez-Sendin M, Di Trani CA, Ardaiz N, Gomar C, Bella A, Aranda F, Medina-Echeverz J, Melero I, Berraondo P.
PMID: 34321273
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2020-001587.

BACKGROUND: Modified vaccinia virus Ankara (MVA) are genetically engineered non-replicating viral vectors. Intratumoral administration of MVA induces a cyclic GMP-AMP synthase-mediated type I interferon (IFN) response and the production of high levels of the transgenes engineered into the viral...

Cite
Tenesaca S, Vasquez M, Alvarez M, et al. Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. J Immunother Cancer. 2021;9(7)doi: 10.1136/jitc-2020-001587.
Tenesaca, S., Vasquez, M., Alvarez, M., Otano, I., Fernandez-Sendin, M., Di Trani, C. A., Ardaiz, N., Gomar, C., Bella, A., Aranda, F., Medina-Echeverz, J., Melero, I., & Berraondo, P. (2021). Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. Journal for immunotherapy of cancer, 9(7), . https://doi.org/10.1136/jitc-2020-001587
Tenesaca, Shirley, et al. "Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors." Journal for immunotherapy of cancer vol. 9,7 (2021). doi: https://doi.org/10.1136/jitc-2020-001587
Tenesaca S, Vasquez M, Alvarez M, Otano I, Fernandez-Sendin M, Di Trani CA, Ardaiz N, Gomar C, Bella A, Aranda F, Medina-Echeverz J, Melero I, Berraondo P. Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2020-001587. PMID: 34321273; PMCID: PMC8320251.
Copy Download .nbib Format: NLM
A Review of Deep Learning Methods for Antibodies.

Antibodies (Basel, Switzerland)

Graves J, Byerly J, Priego E, Makkapati N, Parish SV, Medellin B, Berrondo M.
PMID: 32354020
Antibodies (Basel). 2020 Apr 28;9(2). doi: 10.3390/antib9020012.

Driven by its successes across domains such as computer vision and natural language processing, deep learning has recently entered the field of biology by aiding in cellular image classification, finding genomic connections, and advancing drug discovery. In drug discovery...

Cite
Graves J, Byerly J, Priego E, et al. A Review of Deep Learning Methods for Antibodies. Antibodies (Basel). 2020;9(2)doi: 10.3390/antib9020012.
Graves, J., Byerly, J., Priego, E., Makkapati, N., Parish, S. V., Medellin, B., & Berrondo, M. (2020). A Review of Deep Learning Methods for Antibodies. Antibodies (Basel, Switzerland), 9(2), . https://doi.org/10.3390/antib9020012
Graves, Jordan, et al. "A Review of Deep Learning Methods for Antibodies." Antibodies (Basel, Switzerland) vol. 9,2 (2020). doi: https://doi.org/10.3390/antib9020012
Graves J, Byerly J, Priego E, Makkapati N, Parish SV, Medellin B, Berrondo M. A Review of Deep Learning Methods for Antibodies. Antibodies (Basel). 2020 Apr 28;9(2). doi: 10.3390/antib9020012. PMID: 32354020; PMCID: PMC7344881.
Copy Download .nbib Format: NLM
Firefighters for the Wrong Type of Inflammation in Tumors.

Cancer discovery

Melero I, Teijeira A, Aranda F, Berraondo P.
PMID: 34598950
Cancer Discov. 2021 Oct;11(10):2372-2374. doi: 10.1158/2159-8290.CD-21-1004.

In this issue of

Cite
Melero I, Teijeira A, Aranda F, et al. Firefighters for the Wrong Type of Inflammation in Tumors. Cancer Discov. 2021;11(10):2372-2374doi: 10.1158/2159-8290.CD-21-1004.
Melero, I., Teijeira, A., Aranda, F., & Berraondo, P. (2021). Firefighters for the Wrong Type of Inflammation in Tumors. Cancer discovery, 11(10), 2372-2374. https://doi.org/10.1158/2159-8290.CD-21-1004
Melero, Ignacio, et al. "Firefighters for the Wrong Type of Inflammation in Tumors." Cancer discovery vol. 11,10 (2021): 2372-2374. doi: https://doi.org/10.1158/2159-8290.CD-21-1004
Melero I, Teijeira A, Aranda F, Berraondo P. Firefighters for the Wrong Type of Inflammation in Tumors. Cancer Discov. 2021 Oct;11(10):2372-2374. doi: 10.1158/2159-8290.CD-21-1004. PMID: 34598950.
Copy Download .nbib Format: NLM
Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice.

Frontiers in pharmacology

Ardaiz N, Gomar C, Vasquez M, Tenesaca S, Fernandez-Sendin M, Di Trani CA, Belsué V, Escalada J, Werner U, Tennagels N, Berraondo P.
PMID: 33679386
Front Pharmacol. 2021 Feb 19;11:591293. doi: 10.3389/fphar.2020.591293. eCollection 2020.

No abstract available.

Cite
Ardaiz N, Gomar C, Vasquez M, et al. Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice. Front Pharmacol. 2021;11:591293doi: 10.3389/fphar.2020.591293.
Ardaiz, N., Gomar, C., Vasquez, M., Tenesaca, S., Fernandez-Sendin, M., Di Trani, C. A., Belsué, V., Escalada, J., Werner, U., Tennagels, N., & Berraondo, P. (2020). Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice. Frontiers in pharmacology, 11591293. https://doi.org/10.3389/fphar.2020.591293
Ardaiz, Nuria, et al. "Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice." Frontiers in pharmacology vol. 11 (2020): 591293. doi: https://doi.org/10.3389/fphar.2020.591293
Ardaiz N, Gomar C, Vasquez M, Tenesaca S, Fernandez-Sendin M, Di Trani CA, Belsué V, Escalada J, Werner U, Tennagels N, Berraondo P. Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice. Front Pharmacol. 2021 Feb 19;11:591293. doi: 10.3389/fphar.2020.591293. eCollection 2020. PMID: 33679386; PMCID: PMC7934061.
Copy Download .nbib Format: NLM
Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells.

Oncoimmunology

Medina-Echeverz J, Berraondo P.
PMID: 22720230
Oncoimmunology. 2012 Jan 01;1(1):118-120. doi: 10.4161/onci.1.1.18049.

Interleukin-12 immune stimulation lacks efficacy in established solid tumor models. Disruption of tumor microenvironment homeostasis by low-dose cyclophosphamide prior to interleukin-12 gene therapy led to CD8+ T cell-driven established tumor rejection. This only takes place when inflammatory myeloid cells...

Cite
Medina-Echeverz J, Berraondo P. Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells. Oncoimmunology. 2012;1(1):118-120doi: 10.4161/onci.1.1.18049.
Medina-Echeverz, J., & Berraondo, P. (2012). Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells. Oncoimmunology, 1(1), 118-120. https://doi.org/10.4161/onci.1.1.18049
Medina-Echeverz, José, and Berraondo, Pedro. "Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells." Oncoimmunology vol. 1,1 (2012): 118-120. doi: https://doi.org/10.4161/onci.1.1.18049
Medina-Echeverz J, Berraondo P. Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells. Oncoimmunology. 2012 Jan 01;1(1):118-120. doi: 10.4161/onci.1.1.18049. PMID: 22720230; PMCID: PMC3376964.
Copy Download .nbib Format: NLM
Advances in mRNA-based drug discovery in cancer immunotherapy.

Expert opinion on drug discovery

Di Trani CA, Fernandez-Sendin M, Cirella A, Segués A, Olivera I, Bolaños E, Melero I, Berraondo P.
PMID: 34496689
Expert Opin Drug Discov. 2021 Sep 20;1-13. doi: 10.1080/17460441.2021.1978972. Epub 2021 Sep 20.

INTRODUCTION: Immune checkpoint inhibitors and adoptive T-cell therapy based on chimeric antigen receptors are the spearhead strategies to exploit the immune system to fight cancer. To take advantage of the full potential of the immune system, cancer immunotherapy must...

Cite
Di Trani CA, Fernandez-Sendin M, Cirella A, et al. Advances in mRNA-based drug discovery in cancer immunotherapy. Expert Opin Drug Discov. 2021;1-13doi: 10.1080/17460441.2021.1978972.
Di Trani, C. A., Fernandez-Sendin, M., Cirella, A., Segués, A., Olivera, I., Bolaños, E., Melero, I., & Berraondo, P. (2021). Advances in mRNA-based drug discovery in cancer immunotherapy. Expert opinion on drug discovery, 1-13. https://doi.org/10.1080/17460441.2021.1978972
Di Trani, Claudia Augusta, et al. "Advances in mRNA-based drug discovery in cancer immunotherapy." Expert opinion on drug discovery vol. (2021): 1-13. doi: https://doi.org/10.1080/17460441.2021.1978972
Di Trani CA, Fernandez-Sendin M, Cirella A, Segués A, Olivera I, Bolaños E, Melero I, Berraondo P. Advances in mRNA-based drug discovery in cancer immunotherapy. Expert Opin Drug Discov. 2021 Sep 20;1-13. doi: 10.1080/17460441.2021.1978972. Epub 2021 Sep 20. PMID: 34496689.
Copy Download .nbib Format: NLM
Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers.

Cancers

Mielgo-Rubio X, Calvo V, Luna J, Remon J, Martín M, Berraondo P, Jarabo JR, Higuera O, Conde E, De Castro J, Provencio M, Hernando Trancho F, López-Ríos F, Couñago F.
PMID: 33233705
Cancers (Basel). 2020 Nov 20;12(11). doi: 10.3390/cancers12113459.

Despite numerous advances in targeted therapy and immunotherapy in the last decade, lung cancer continues to present the highest mortality rate of all cancers. Targeted therapy based on specific genomic alterations, together with PD-1 and CTLA-4 axis blocking-based immunotherapy,...

Cite
Mielgo-Rubio X, Calvo V, Luna J, et al. Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers. Cancers (Basel). 2020;12(11)doi: 10.3390/cancers12113459.
Mielgo-Rubio, X., Calvo, V., Luna, J., Remon, J., Martín, M., Berraondo, P., Jarabo, J. R., Higuera, O., Conde, E., De Castro, J., Provencio, M., Hernando Trancho, F., López-Ríos, F., & Couñago, F. (2020). Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers. Cancers, 12(11), . https://doi.org/10.3390/cancers12113459
Mielgo-Rubio, Xabier, et al. "Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers." Cancers vol. 12,11 (2020). doi: https://doi.org/10.3390/cancers12113459
Mielgo-Rubio X, Calvo V, Luna J, Remon J, Martín M, Berraondo P, Jarabo JR, Higuera O, Conde E, De Castro J, Provencio M, Hernando Trancho F, López-Ríos F, Couñago F. Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers. Cancers (Basel). 2020 Nov 20;12(11). doi: 10.3390/cancers12113459. PMID: 33233705; PMCID: PMC7699975.
Copy Download .nbib Format: NLM
Idiopathic non-ischemic priapism in an infant: A case report.

Urology case reports

Wang LL, Berrondo C.
PMID: 33102124
Urol Case Rep. 2020 Sep 23;33:101428. doi: 10.1016/j.eucr.2020.101428. eCollection 2020 Nov.

Priapism is a pathologic erection lasting >4 hours that is unrelated to or persists beyond sexual stimulation. Priapism is rare in children, and rarely reported in infants. Although a small number of cases have been reported in neonates, even...

Cite
Wang LL, Berrondo C. Idiopathic non-ischemic priapism in an infant: A case report. Urol Case Rep. 2020;33:101428doi: 10.1016/j.eucr.2020.101428.
Wang, L. L., & Berrondo, C. (2020). Idiopathic non-ischemic priapism in an infant: A case report. Urology case reports, 33101428. https://doi.org/10.1016/j.eucr.2020.101428
Wang, Luke L, and Berrondo, Claudia. "Idiopathic non-ischemic priapism in an infant: A case report." Urology case reports vol. 33 (2020): 101428. doi: https://doi.org/10.1016/j.eucr.2020.101428
Wang LL, Berrondo C. Idiopathic non-ischemic priapism in an infant: A case report. Urol Case Rep. 2020 Sep 23;33:101428. doi: 10.1016/j.eucr.2020.101428. eCollection 2020 Nov. PMID: 33102124; PMCID: PMC7574272.
Copy Download .nbib Format: NLM
IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research

Teijeira A, Garasa S, Ochoa MC, Villalba M, Olivera I, Cirella A, Eguren-Santamaria I, Berraondo P, Schalper KA, de Andrea CE, Sanmamed MF, Melero I.
PMID: 33376096
Clin Cancer Res. 2021 May 01;27(9):2383-2393. doi: 10.1158/1078-0432.CCR-20-1319. Epub 2020 Dec 29.

One of the most important mechanisms by which cancer fosters its own development is the generation of an immune microenvironment that inhibits or impairs antitumor immune responses. A cancer permissive immune microenvironment is present in a large proportion of...

Cite
Teijeira A, Garasa S, Ochoa MC, et al. IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy. Clin Cancer Res. 2020;27(9):2383-2393doi: 10.1158/1078-0432.CCR-20-1319.
Teijeira, A., Garasa, S., Ochoa, M. C., Villalba, M., Olivera, I., Cirella, A., Eguren-Santamaria, I., Berraondo, P., Schalper, K. A., de Andrea, C. E., Sanmamed, M. F., & Melero, I. (2021). IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(9), 2383-2393. https://doi.org/10.1158/1078-0432.CCR-20-1319
Teijeira, Alvaro, et al. "IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,9 (2021): 2383-2393. doi: https://doi.org/10.1158/1078-0432.CCR-20-1319
Teijeira A, Garasa S, Ochoa MC, Villalba M, Olivera I, Cirella A, Eguren-Santamaria I, Berraondo P, Schalper KA, de Andrea CE, Sanmamed MF, Melero I. IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy. Clin Cancer Res. 2021 May 01;27(9):2383-2393. doi: 10.1158/1078-0432.CCR-20-1319. Epub 2020 Dec 29. PMID: 33376096.
Copy Download .nbib Format: NLM
CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function.

Cancer immunology research

Cabo M, Santana-Hernández S, Costa-Garcia M, Rea A, Lozano-Rodríguez R, Ataya M, Balaguer F, Juan M, Ochoa MC, Menéndez S, Comerma L, Rovira A, Berraondo P, Albanell J, Melero I, López-Botet M, Muntasell A.
PMID: 34580116
Cancer Immunol Res. 2021 Dec;9(12):1476-1490. doi: 10.1158/2326-6066.CIR-21-0030. Epub 2021 Sep 27.

Enhancing natural killer (NK) cell-based cancer immunotherapy by overcoming immunosuppression is an area of intensive research. Here, we have demonstrated that the anti-CD137 agonist urelumab can overcome TGFβ-mediated inhibition of human NK-cell proliferation and antitumor function. Transcriptomic, immunophenotypic, and...

Cite
Cabo M, Santana-Hernández S, Costa-Garcia M, et al. CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function. Cancer Immunol Res. 2021;9(12):1476-1490doi: 10.1158/2326-6066.CIR-21-0030.
Cabo, M., Santana-Hernández, S., Costa-Garcia, M., Rea, A., Lozano-Rodríguez, R., Ataya, M., Balaguer, F., Juan, M., Ochoa, M. C., Menéndez, S., Comerma, L., Rovira, A., Berraondo, P., Albanell, J., Melero, I., López-Botet, M., & Muntasell, A. (2021). CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function. Cancer immunology research, 9(12), 1476-1490. https://doi.org/10.1158/2326-6066.CIR-21-0030
Cabo, Mariona, et al. "CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function." Cancer immunology research vol. 9,12 (2021): 1476-1490. doi: https://doi.org/10.1158/2326-6066.CIR-21-0030
Cabo M, Santana-Hernández S, Costa-Garcia M, Rea A, Lozano-Rodríguez R, Ataya M, Balaguer F, Juan M, Ochoa MC, Menéndez S, Comerma L, Rovira A, Berraondo P, Albanell J, Melero I, López-Botet M, Muntasell A. CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function. Cancer Immunol Res. 2021 Dec;9(12):1476-1490. doi: 10.1158/2326-6066.CIR-21-0030. Epub 2021 Sep 27. PMID: 34580116.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 43 entries